Cantillon Capital Management LLC reduced its stake in shares of Allergan PLC. (NYSE:AGN) by 4.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,002,451 shares of the company’s stock after selling 42,000 shares during the period. Allergan PLC. accounts for approximately 3.0% of Cantillon Capital Management LLC’s investment portfolio, making the stock its 18th biggest position. Cantillon Capital Management LLC owned approximately 0.30% of Allergan PLC. worth $243,686,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Honeywell International Inc. raised its position in shares of Allergan PLC. by 13.6% in the 2nd quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after acquiring an additional 20,100 shares in the last quarter. Israel Discount Bank of New York bought a new position in shares of Allergan PLC. in the 1st quarter worth about $988,000. Trust Co. of Vermont raised its position in shares of Allergan PLC. by 62.8% in the 1st quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after acquiring an additional 1,109 shares in the last quarter. Palladium Partners LLC raised its position in shares of Allergan PLC. by 1.7% in the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after acquiring an additional 523 shares in the last quarter. Finally, Capital Planning Advisors LLC raised its position in shares of Allergan PLC. by 79.3% in the 1st quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock worth $878,000 after acquiring an additional 1,625 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently commented on AGN shares. Cowen and Company set a $400.00 target price on Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, June 8th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Mizuho reduced their target price on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Royal Bank Of Canada restated a “buy” rating and issued a $285.00 target price on shares of Allergan PLC. in a research note on Wednesday, September 6th. Finally, Cantor Fitzgerald started coverage on Allergan PLC. in a research note on Friday, June 16th. They issued a “neutral” rating and a $231.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $274.69.

Shares of Allergan PLC. (NYSE:AGN) opened at 231.21 on Wednesday. The company has a market cap of $77.29 billion, a PE ratio of 7.04 and a beta of 1.18. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The company has a 50 day moving average of $235.09 and a 200-day moving average of $237.04.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter last year, the company posted $3.35 earnings per share. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. Equities research analysts anticipate that Allergan PLC. will post $16.25 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.21%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is currently 9.95%.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/13/cantillon-capital-management-llc-has-243-69-million-position-in-allergan-plc-agn.html.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.